000			01967 a2200565 4500
005			20250517075948.0
264		0	_c20160712
008			201607s 0 0 eng d
022			_a1879-0852
024	7		_a10.1016/j.ejca.2015.12.019 _2doi
040			_aNLM _beng _cNLM
100	1		_aKloth, Jacqueline S L
245	0	0	_aMacrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment. _h[electronic resource]
260			_bEuropean journal of cancer (Oxford, England : 1990) _cMar 2016
300			_a101-106 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aCarcinoma, Renal Cell _xblood
650	0	4	_aDisease-Free Survival
650	0	4	_aErythrocyte Indices
650	0	4	_aErythrocytes _xdrug effects
650	0	4	_aFemale
650	0	4	_aHemoglobins _xmetabolism
650	0	4	_aHumans
650	0	4	_aIndoles _xadverse effects
650	0	4	_aKidney Neoplasms _xblood
650	0	4	_aMale
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aPredictive Value of Tests
650	0	4	_aProportional Hazards Models
650	0	4	_aProtein Kinase Inhibitors _xadverse effects
650	0	4	_aProtein-Tyrosine Kinases _xantagonists & inhibitors
650	0	4	_aPyrroles _xadverse effects
650	0	4	_aRetrospective Studies
650	0	4	_aRisk Factors
650	0	4	_aSunitinib
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aHamberg, Paul
700	1		_aMendelaar, Pauline A J
700	1		_aDulfer, Roderick R
700	1		_avan der Holt, Bronno
700	1		_aEechoute, Karel
700	1		_aWiemer, Erik A C
700	1		_aKruit, Wim H J
700	1		_aSleijfer, Stefan
700	1		_aMathijssen, Ron H J
773	0		_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 56 _gp. 101-106
856	4	0	_uhttps://doi.org/10.1016/j.ejca.2015.12.019 _zAvailable from publisher's website
999			_c25698570 _d25698570